The findings, published in the journal Diabetes, Obesity and Metabolism, provide real-world context to previous randomized clinical trials indicating that patients who stopped semaglutide (sold under the brand names Ozempic/Wegovy) and tirzepatide (sold under the brand names Mounjaro/Zepbound) regained more than half of the weight they lost within 12 months
Large-scale clinical trials have demonstrated that GLP-1RAs reduce the incidence of major adverse cardiovascular events (MACE), including myocardial infarction (MI) and stroke, through metabolic, anti-inflammatory, and direct cardiac mechanisms in both diabetic and non-diabetic populations [316,317,318]
I dont feel like Im dragging anymore. So far, he has experienced no side effects and plans to continue microdosing as long as his A1C and cholesterol numbers stay within the normal range
Use of GLP-1 receptor agonists and subsequent risk of alcohol-related events
GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), liraglutide (Victoza, Saxenda), and tirzepatide (Mounjaro, Zepbound) are FDA-approved for type 2 diabetes and obesity management
The impact has been vast and further preclinical studies are still necessary to explore and understand the potential of the drugs that have already revolutionised the lives of millions of people with obesity and type 2 diabetes
